0001144204-18-014636.txt : 20180314 0001144204-18-014636.hdr.sgml : 20180314 20180314160114 ACCESSION NUMBER: 0001144204-18-014636 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180312 FILED AS OF DATE: 20180314 DATE AS OF CHANGE: 20180314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CARUSO JAMES V CENTRAL INDEX KEY: 0001202770 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 18689458 MAIL ADDRESS: STREET 1: C/O CELLECTAR BIOSCIENCES, INC. STREET 2: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 4 1 tv488453_4.xml OWNERSHIP DOCUMENT X0306 4 2018-03-12 0 0001279704 Cellectar Biosciences, Inc. CLRB 0001202770 CARUSO JAMES V C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716 1 1 0 0 President and CEO Common Stock 2018-03-12 4 S 0 34000 1.1972 D 213548 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2017 to satisfy tax withholding obligations upon vesting of restricted stock. The price reported in Column 4 of Line 1 with respect to the 34,000 shares sold on March 12, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.26. The Reporting Person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4. /s/ Christina Blakley, attorney-in-fact for James Caruso 2018-03-14